BMS-564,929
BMS-564,929 is an androgen/anabolic steroid (AAS) which was developed by Bristol-Myers Squibb for the treatment of hypogonadism and muscle wasting conditions. It is a selective androgen receptor modulator (SARM), a class of drugs that have similar effects to AAS but with reduced androgenic side effects.
History[edit]
BMS-564,929 was first synthesized and studied by Bristol-Myers Squibb in the early 2000s. The aim was to develop a drug that could provide the benefits of AAS, such as increased muscle mass and strength, without the associated side effects such as prostate enlargement and cardiovascular disease.
Pharmacology[edit]
BMS-564,929 acts as a selective androgen receptor modulator. It binds to the androgen receptor (AR) with high affinity and selectivity, and activates the receptor in a tissue-selective manner. This means it can stimulate muscle growth and strength without causing unwanted side effects in other tissues.
Clinical trials[edit]
Several clinical trials have been conducted to assess the safety and efficacy of BMS-564,929. These trials have shown that the drug is well-tolerated and can increase muscle mass and strength in men with hypogonadism or muscle wasting conditions. However, further research is needed to fully understand the long-term effects and potential uses of this drug.
Potential uses[edit]
BMS-564,929 has potential uses in the treatment of conditions such as hypogonadism, muscle wasting associated with cancer, HIV/AIDS, and aging, and potentially in the treatment of osteoporosis. However, more research is needed to confirm these potential uses and to determine the optimal dosing and administration protocols.
See also[edit]
